Literature DB >> 21216550

A case of Budd-Chiari syndrome: Gd-EOB-DTPA-enhanced MR findings.

Kazuhiro Kitajima1, Takeshi Yoshikawa, Yasushi Seo, Yoshiharu Ohno, Yoshihiko Yano, Akira Miki, Tomonori Kanda, Naoki Kanata, Takeshi Azuma, Kazuro Sugimura.   

Abstract

Budd-Chiari syndrome (BCS) is a rare disorder caused by the obstruction of hepatic venous outflow, leading to sinusoidal congestion, ischemic injury to liver cells and portal hypertension. Long-term survival largely depends on whether hepatocellular carcinoma occurs. A recently available liver-specific contrast medium, gadolinium-ethoxybenzyl-diethylenetriamine penta-acetic acid (Gd-EOB-DTPA), reportedly has high diagnostic capability for detection of malignant liver tumors. However, there has been no report of the sue of Gd-EOB-DTPA-enhanced magnetic resonance imaging (MRI) for BCS. We present a case of chronic BCS who underwent both gadopentetate dimeglumine (Gd-DTPA) and Gd-EOB-DTPA-enhanced MRI. Hepatic congestion and edema were seen as slightly hypointense areas on Gd-EOB-DTPA-enhanced hepatobiliary-phase images, although these areas were observed as slightly hyperintense on previously obtained Gd-DTPA-enhanced delayed-phase image. Reduced uptake of Gd-EOB-DTPA by hepatocytes in the region of congestion or edema may account for this difference, which should be recognized in image interpretations.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21216550     DOI: 10.1016/j.mri.2010.10.013

Source DB:  PubMed          Journal:  Magn Reson Imaging        ISSN: 0730-725X            Impact factor:   2.546


  2 in total

1.  Imaging and interventions in Budd-Chiari syndrome.

Authors:  Amar Mukund; Shivanand Gamanagatti
Journal:  World J Radiol       Date:  2011-07-28

2.  ESGAR consensus statement on liver MR imaging and clinical use of liver-specific contrast agents.

Authors:  E Neri; M A Bali; A Ba-Ssalamah; P Boraschi; G Brancatelli; F Caseiro Alves; L Grazioli; T Helmberger; J M Lee; R Manfredi; L Martì-Bonmatì; C Matos; E M Merkle; B Op De Beeck; W Schima; S Skehan; V Vilgrain; C Zech; C Bartolozzi
Journal:  Eur Radiol       Date:  2015-07-21       Impact factor: 5.315

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.